Chongqing Precision Biotech Co., Ltd
Privately held: no public share price
Assets
(3 total)
3Total Assets
0Approved
0Phase 3 / Filed
3Phase 1–2 / Early
2Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Phase 1/2 | BCMACell therapy | Multiple Myeloma | |
| Phase 1/2 | CD123Cell therapy | Acute Myeloid Leukemia | |
C-4-29No recent activity | Phase 1 | BCMA; CD70Cell therapy | Multiple Myeloma |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
December 2026 (1)
BCMA-targeted Prime CAR-T cells (Chongqing Precision Biotech)Phase 1/2Multiple Myeloma, Neoplasm, Plasma Cell, Multiple Myeloma in Relapse
Est. primary completion 2026-12-31 · NCT04776330 · CT.gov ↗
What to watch
Financial reports
No financial reports recorded.